Targeting Inflammation in the Gut with Transferrin Receptor Immunoliposomes
Author Information
Author(s): Harel Efrat, Rubinstein Abraham, Nissan Aviram, Khazanov Elena, Nadler Milbauer Mirela, Barenholz Yechezkel, Tirosh Boaz
Primary Institution: Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Hypothesis
We hypothesized that transferrin receptor (TfR) expression is regulated in enterocytes and can be targeted for drug delivery to inflamed gut mucosa.
Conclusion
The study concluded that targeting mucosal inflammation can be effectively achieved using nano-liposomes decorated with anti-TfR antibodies.
Supporting Evidence
- TfR expression was elevated in the colonic mucosa of IBD patients.
- Increased TfR expression was also observed in colonocytes of induced colitis rats.
- Proinflammatory cytokines increased TfR expression and transferrin uptake in Caco-2 cells.
- Anti-TfR immunoliposomes accumulated significantly better in inflamed mucosa compared to non-specific immunoliposomes.
Takeaway
The researchers found that a special protein called transferrin receptor is more common in inflamed parts of the gut, which can help deliver medicine directly to those areas.
Methodology
The study involved comparing TfR expression in healthy and inflamed human colonic mucosa and in a rat model of induced colitis, along with in vitro experiments using Caco-2 cells.
Potential Biases
Potential bias may arise from the use of a single animal model and the specific cytokines chosen for the study.
Limitations
The study did not explore the long-term effects of the immunoliposomes in vivo or their potential side effects.
Participant Demographics
The study included human specimens from 9 IBD patients and male Sabra rats.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website